{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:26:37Z","timestamp":1790630797522,"version":"4.1.0"},"reference-count":100,"publisher":"Japan Atherosclerosis Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2018]]},"DOI":"10.5551\/jat.rv17010","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T18:07:58Z","timestamp":1500487678000},"page":"16-26","source":"Crossref","is-referenced-by-count":133,"title":["Sphingosine 1-Phosphate and Atherosclerosis"],"prefix":"10.5551","volume":"25","author":[{"given":"Makoto","family":"Kurano","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yatomi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Goetzl EJ: Pleiotypic mechanisms of cellular responses to biologically active lysophospholipids. Prostaglandins, 2001; 64: 11-20","DOI":"10.1016\/S0090-6980(01)00104-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D: Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest, 2001; 108: 689-701","DOI":"10.1172\/JCI12450"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science, 2002; 296: 346-349","DOI":"10.1126\/science.1070238"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Pyne NJ, Pyne S: Sphingosine 1-phosphate and cancer. Nat Rev Cancer, 2010; 10: 489-503","DOI":"10.1038\/nrc2875"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ng ML, Wadham C, Sukocheva OA: The role of sphingolipid signalling in diabetesassociated pathologies (Review). Int J Mol Med, 2017; 39: 243-252","DOI":"10.3892\/ijmm.2017.2855"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kawahara A, Nishi T, Hisano Y, Fukui H, Yamaguchi A, Mochizuki N: The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science, 2009; 323: 524-527","DOI":"10.1126\/science.1167449"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Koch A, Pfeilschifter J, Huwiler A: Sphingosine 1-phosphate in renal diseases. Cell Physiol Biochem, 2013; 31: 745-760","DOI":"10.1159\/000350093"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mao-Draayer Y, Sarazin J, Fox D, Schiopu E: The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin Immunol, 2017; 175: 10-15","DOI":"10.1016\/j.clim.2016.11.008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Okajima F: Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta, 2002; 1582: 132-137","DOI":"10.1016\/S1388-1981(02)00147-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Xu N, Dahlback B: A novel human apolipoprotein (apoM). J Biol Chem, 1999; 274: 31286-31290","DOI":"10.1074\/jbc.274.44.31286"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B: Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A, 2011; 108: 9613-9618","DOI":"10.1073\/pnas.1103187108"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Brewer HB, Jr.: Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab, 2011; 96: 1246-1257","DOI":"10.1210\/jc.2010-0163"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Levkau B: HDL-S1P: cardiovascular functions, diseaseassociated alterations, and therapeutic applications. Front Pharmacol, 2015; 6: 243","DOI":"10.3389\/fphar.2015.00243"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Le Stunff H, Milstien S, Spiegel S: Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem, 2004; 92: 882-899","DOI":"10.1002\/jcb.20097"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR: Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science, 2007; 316: 295-298","DOI":"10.1126\/science.1139221"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Yatomi Y, Ruan F, Hakomori S, Igarashi Y: Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood, 1995; 86: 193-202","DOI":"10.1182\/blood.V86.1.193.bloodjournal861193"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, Hla T: Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res, 2008; 102: 669-676","DOI":"10.1161\/CIRCRESAHA.107.165845"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Jonnalagadda D, Sunkara M, Morris AJ, Whiteheart SW: Granule-mediated release of sphingosine-1-phosphate by activated platelets. Biochim Biophys Acta, 2014; 1841: 1581-1589","DOI":"10.1016\/j.bbalip.2014.08.013"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kobayashi N, Nishi T, Hirata T, Kihara A, Sano T, Igarashi Y, Yamaguchi A: Sphingosine 1-phosphate is released from the cytosol of rat platelets in a carriermediated manner. J Lipid Res, 2006; 47: 614-621","DOI":"10.1194\/jlr.M500468-JLR200"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kobayashi N, Yamaguchi A, Nishi T: Characterization of the ATP-dependent sphingosine 1-phosphate transporter in rat erythrocytes. J Biol Chem, 2009; 284: 21192-21200","DOI":"10.1074\/jbc.M109.006163"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kurano M, Nishikawa M, Kuma H, Jona M, Yatomi Y: Involvement of Band3 in the efflux of sphingosine 1-phosphate from erythrocytes. PLoS One, 2017; 12: e0177543","DOI":"10.1371\/journal.pone.0177543"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Fukuhara S, Simmons S, Kawamura S, Inoue A, Orba Y, Tokudome T, Sunden Y, Arai Y, Moriwaki K, Ishida J, Uemura A, Kiyonari H, Abe T, Fukamizu A, Hirashima M, Sawa H, Aoki J, Ishii M, Mochizuki N: The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest, 2012; 122: 1416-1426","DOI":"10.1172\/JCI60746"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sciorra VA, Morris AJ: Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim Bio phys Acta, 2002; 1582: 45-51","DOI":"10.1016\/S1388-1981(02)00136-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Yu Y, Guo S, Feng Y, Feng L, Cui Y, Song G, Luo T, Zhang K, Wang Y, Jiang XC, Qin S: Phospholipid transfer protein deficiency decreases the content of S1P in HDL via the loss of its transfer capability. Lipids, 2014; 49: 183-190","DOI":"10.1007\/s11745-013-3850-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kimura T, Sato K, Kuwabara A, Tomura H, Ishiwara M, Kobayashi I, Ui M, Okajima F: Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem, 2001; 276: 31780-31785","DOI":"10.1074\/jbc.M104353200"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G: Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem, 2001; 276: 34480-34485","DOI":"10.1074\/jbc.M103782200"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A, Murakami M, Okajima F: High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol, 2003; 23: 1283-1288","DOI":"10.1161\/01.ATV.0000079011.67194.5A"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Feuerborn R, Becker S, Poti F, Nagel P, Brodde M, Schmidt H, Christoffersen C, Ceglarek U, Burkhardt R, Nofer JR: High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression. Atherosclerosis, 2017; 257: 29-37","DOI":"10.1016\/j.atherosclerosis.2016.12.009"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3.J Clin Invest, 2004; 113: 569-581","DOI":"10.1172\/JCI18004"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kimura T, Tomura H, Mogi C, Kuwabara A, Damirin A, Ishizuka T, Sekiguchi A, Ishiwara M, Im DS, Sato K, Murakami M, Okajima F: Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem, 2006; 281: 37457-37467","DOI":"10.1074\/jbc.M605823200"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Igarashi J, Miyoshi M, Hashimoto T, Kubota Y, Kosaka H: Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins. Br J Pharmacol, 2007; 150: 470-479","DOI":"10.1038\/sj.bjp.0707114"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kimura T, Mogi C, Tomura H, Kuwabara A, Im DS, Sato K, Kurose H, Murakami M, Okajima F: Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. J Immunol, 2008; 181: 7332-7340","DOI":"10.4049\/jimmunol.181.10.7332"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Xu M, Waters CL, Hu C, Wysolmerski RB, Vincent PA, Minnear FL: Sphingosine 1-phosphate rapidly increases endothelial barrier function independently of VE-cadherin but requires cell spreading and Rho kinase. Am J Physiol Cell Physiol, 2007; 293: C1309-1318","DOI":"10.1152\/ajpcell.00014.2007"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, Hammad SM, Argraves WS: High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem, 2008; 283: 25074-25081","DOI":"10.1074\/jbc.M801214200"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Filep JG, Foldes-Filep E, Sirois P: Nitric oxide modulates vascular permeability in the rat coronary circulation. Br J Pharmacol, 1993; 108: 323-326","DOI":"10.1111\/j.1476-5381.1993.tb12803.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Ruiz M, Frej C, Holmer A, Guo LJ, Tran S, Dahlback B: High-Density Lipoprotein-Associated Apolipoprotein M Limits Endothelial Inflammation by Delivering Sphingosine-1-Phosphate to the Sphingosine-1-Phosphate Receptor 1. Arterioscler Thromb Vasc Biol, 2017; 37: 118-129","DOI":"10.1161\/ATVBAHA.116.308435"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Duenas AI, Aceves M, Fernandez-Pisonero I, Gomez C, Orduna A, Crespo MS, Garcia-Rodriguez C: Selective attenuation of Toll-like receptor 2 signalling may explain the atheroprotective effect of sphingosine 1-phosphate. Cardiovasc Res, 2008; 79: 537-544","DOI":"10.1093\/cvr\/cvn087"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Tamama K, Tomura H, Sato K, Malchinkhuu E, Damirin A, Kimura T, Kuwabara A, Murakami M, Okajima F: High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis, 2005; 178: 19-23","DOI":"10.1016\/j.atherosclerosis.2004.07.032"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Frias MA, James RW, Gerber-Wicht C, Lang U: Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1\/2: role of sphingosine-1-phosphate. Cardiovasc Res, 2009; 82: 313-323","DOI":"10.1093\/cvr\/cvp024"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, Raffai R: High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol, 2010; 298: H1022-1028","DOI":"10.1152\/ajpheart.00902.2009"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Pelletier D, Hafler DA: Fingolimod for multiple sclerosis.N Engl J Med, 2012; 366: 339-347","DOI":"10.1056\/NEJMct1101691"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Goetzl EJ, Graler MH: Sphingosine 1-phosphate and its type 1 G protein-coupled receptor: trophic support and functional regulation of T lymphocytes. J Leukoc Biol, 2004; 76: 30-35","DOI":"10.1189\/jlb.1103567"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Swan DJ, Kirby JA, Ali S: Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammation. J Cell Mol Med, 2010; 14: 2211-2222","DOI":"10.1111\/j.1582-4934.2010.01136.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Shatrov VA, Lehmann V, Chouaib S: Sphingosine-1-phosphate mobilizes intracellular calcium and activates transcription factor NF-kappa B in U937 cells. Biochem Biophys Res Commun, 1997; 234: 121-124","DOI":"10.1006\/bbrc.1997.6598"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Keul P, Lucke S, von Wnuck Lipinski K, Bode C, Graler M, Heusch G, Levkau B: Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte\/macrophages in inflammation and atherosclerosis. Circ Res, 2011; 108: 314-323","DOI":"10.1161\/CIRCRESAHA.110.235028"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Lewis ND, Haxhinasto SA, Anderson SM, Stefanopoulos DE, Fogal SE, Adusumalli P, Desai SN, Patnaude LA, Lukas SM, Ryan KR, Slavin AJ, Brown ML, Modis LK: Circulating monocytes are reduced by sphingosine1-phosphate receptor modulators independently of S1P3.J Immunol, 2013; 190: 3533-3540","DOI":"10.4049\/jimmunol.1201810"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Allende ML, Zhou D, Kalkofen DN, Benhamed S, Tuymetova G, Borowski C, Bendelac A, Proia RL: S1P1 receptor expression regulates emergence of NKT cells in peripheral tissues. FASEB J, 2008; 22: 307-315","DOI":"10.1096\/fj.07-9087com"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, Xu Y, Roots CM, Beilke JN, Banerjee A, Reiner SL, Miller SA, Weinmann AS, Goodnow CC, Lanier LL, Cyster JG, Chun J: T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med, 2009; 206: 2469- 2481","DOI":"10.1084\/jem.20090525"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Grimm M, Tischner D, Troidl K, Albarran Juarez J, Sivaraj KK, Ferreiros Bouzas N, Geisslinger G, Binder CJ, Wettschureck N: S1P2\/G12\/13 Signaling Negatively Regulates Macrophage Activation and Indirectly Shapes the Atheroprotective B1-Cell Population. Arterioscler Thromb Vasc Biol, 2016; 36: 37-48","DOI":"10.1161\/ATVBAHA.115.306066"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Takeya H, Gabazza EC, Aoki S, Ueno H, Suzuki K: Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood, 2003; 102: 1693-1700","DOI":"10.1182\/blood-2002-11-3607"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Lee MH, Hammad SM, Semler AJ, Luttrell LM, Lopes-Virella MF, Klein RL: HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate. J Lipid Res, 2010; 51: 2619-2628","DOI":"10.1194\/jlr.M003988"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Ito S, Iwaki S, Koike K, Yuda Y, Nagasaki A, Ohkawa R, Yatomi Y, Furumoto T, Tsutsui H, Sobel BE, Fujii S: Increased plasma sphingosine-1-phosphate in obese individuals and its capacity to increase the expression of plasminogen activator inhibitor-1 in adipocytes. Coron Artery Dis, 2013; 24: 642-650","DOI":"10.1097\/MCA.0000000000000033"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Iwaki S, Yamamura S, Asai M, Sobel BE, Fujii S: Posttranscriptional regulation of expression of plasminogen activator inhibitor type-1 by sphingosine 1-phosphate in HepG2 liver cells. Biochim Biophys Acta, 2012; 1819: 1132-1141","DOI":"10.1016\/j.bbagrm.2012.07.001"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Bryan L, Paugh BS, Kapitonov D, Wilczynska KM, Alvarez SM, Singh SK, Milstien S, Spiegel S, Kordula T: Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Mol Cancer Res, 2008; 6: 1469-1477","DOI":"10.1158\/1541-7786.MCR-08-0082"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Bohm A, Flosser A, Ermler S, Fender AC, Luth A, Kleuser B, Schror K, Rauch BH: Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells. Cardiovasc Res, 2013; 99: 505-513","DOI":"10.1093\/cvr\/cvt112"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Urtz N, Gaertner F, von Bruehl ML, Chandraratne S, Rahimi F, Zhang L, Orban M, Barocke V, Beil J, Schubert I, Lorenz M, Legate KR, Huwiler A, Pfeilschifter JM, Beerli C, Ledieu D, Persohn E, Billich A, Baumruker T, Mederos y Schnitzler M, Massberg S: Sphingosine 1-Phosphate Produced by Sphingosine Kinase 2 Intrinsically Controls Platelet Aggregation In Vitro and In Vivo. Circ Res, 2015; 117: 376-387","DOI":"10.1161\/CIRCRESAHA.115.306901"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T: Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol, 2007; 27: 1312-1318","DOI":"10.1161\/ATVBAHA.107.143735"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B: High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia\/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation, 2006; 114: 1403-1409","DOI":"10.1161\/CIRCULATIONAHA.105.607135"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, Hla T: Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol, 2011; 31: 81-85","DOI":"10.1161\/ATVBAHA.110.213496"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL: Edg-1, the G proteincoupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest, 2000; 106: 951-961","DOI":"10.1172\/JCI10905"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Poti F, Gualtieri F, Sacchi S, Weissen-Plenz G, Varga G, Brodde M, Weber C, Simoni M, Nofer JR: KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-\/- mice. Arterioscler Thromb Vasc Biol, 2013; 33: 1505-1512","DOI":"10.1161\/ATVBAHA.113.301347"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Poti F, Ceglarek U, Burkhardt R, Simoni M, Nofer JR: SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-\/-) mice on high cholesterol diet. Atherosclerosis, 2015; 240: 212-215","DOI":"10.1016\/j.atherosclerosis.2015.03.020"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Wolfrum C, Poy MN, Stoffel M: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med, 2005; 11: 418-422","DOI":"10.1038\/nm1211"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Kurano M, Tsukamoto K, Ohkawa R, Hara M, Iino J, Kageyama Y, Ikeda H, Yatomi Y: Liver involvement in sphingosine 1-phosphate dynamism revealed by adenoviral hepatic overexpression of apolipoprotein M. Atherosclerosis, 2013; 229: 102-109","DOI":"10.1016\/j.atherosclerosis.2013.04.024"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Liu M, Seo J, Allegood J, Bi X, Zhu X, Boudyguina E, Gebre AK, Avni D, Shah D, Sorci-Thomas MG, Thomas MJ, Shelness GS, Spiegel S, Parks JS: Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM\/sphingosine 1-phosphateenriched plasma high density lipoprotein. J Biol Chem, 2014; 289: 2801-2814","DOI":"10.1074\/jbc.M113.499913"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Liu M, Allegood J, Zhu X, Seo J, Gebre AK, Boudyguina E, Cheng D, Chuang CC, Shelness GS, Spiegel S, Parks JS: Uncleaved ApoM signal peptide is required for formation of large ApoM\/sphingosine 1-phosphate (S1P)-enriched HDL particles. J Biol Chem, 2015; 290: 7861-7870","DOI":"10.1074\/jbc.M114.631101"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I, Kuivenhoven JA, Rohrer L, Matile H, Hornemann T, Stoffel M, Rentsch KM, von Eckardstein A: Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis, 2011; 219: 855-863","DOI":"10.1016\/j.atherosclerosis.2011.08.049"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Takahashi C, Kurano M, Nishikawa M, Kano K, Dohi T, Miyauchi K, Daida H, Shimizu T, Aoki J, Yatomi Y: Vehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression. J Atheroscler Thromb, 2017; 24:954-969","DOI":"10.5551\/jat.37663"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Sevvana M, Ahnstrom J, Egerer-Sieber C, Lange HA, Dahlback B, Muller YA: Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol, 2009; 393: 920-936","DOI":"10.1016\/j.jmb.2009.08.071"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Ohkawa R, Nakamura K, Okubo S, Hosogaya S, Ozaki Y, Tozuka M, Osima N, Yokota H, Ikeda H, Yatomi Y: Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ann Clin Biochem, 2008; 45: 356-363","DOI":"10.1258\/acb.2007.007189"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Kurano M, Tsukamoto K, Hara M, Ohkawa R, Ikeda H, Yatomi Y: LDL receptor and ApoE are involved in the clearance of ApoM-associated sphingosine 1-phosphate. J Biol Chem, 2015; 290: 2477-2488","DOI":"10.1074\/jbc.M114.596445"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Kappelle PJ, Ahnstrom J, Dikkeschei BD, de Vries R, Sluiter WJ, Wolffenbuttel BH, van Tol A, Nielsen LB, Dahlback B, Dullaart RP: Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. Atherosclerosis, 2010; 213: 247-250","DOI":"10.1016\/j.atherosclerosis.2010.07.048"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Thongtang N, Diffenderfer MR, Ooi EM, Barrett PH, Turner SM, Le NA, Brown WV, Schaefer EJ: Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia. Effects of rosuvastatin. J Lipid Res, 2017;","DOI":"10.1194\/jlr.M073882"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Rader DJ, deGoma EM: Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med, 2014; 65: 385-403","DOI":"10.1146\/annurev-med-050311-163305"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Kurano M, Hara M, Ikeda H, Tsukamoto K, Yatomi Y: Involvement of CETP (Cholesteryl Ester Transfer Protein) in the Shift of Sphingosine-1-Phosphate Among Lipoproteins and in the Modulation of its Functions. Arterioscler Thromb Vasc Biol, 2017; 37: 506-514","DOI":"10.1161\/ATVBAHA.116.308692"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Kurano M, Hara M, Nojiri T, Ikeda H, Tsukamoto K, Yatomi Y: Resveratrol exerts a biphasic effect on apolipoprotein M. Br J Pharmacol, 2016; 173: 222-233","DOI":"10.1111\/bph.13360"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ: Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review). Int J Mol Med, 2001; 8: 3-17","DOI":"10.3892\/ijmm.8.1.3"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Nojiri T, Kurano M, Tokuhara Y, Ohkubo S, Hara M, Ikeda H, Tsukamoto K, Yatomi Y: Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma, liver and kidneys in streptozotocin-induced diabetic mice. J Diabetes Investig, 2014; 5: 639-648","DOI":"10.1111\/jdi.12232"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Xu N, Nilsson-Ehle P, Ahren B: Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. Biochem Biophys Res Commun, 2006; 342: 1174-1177","DOI":"10.1016\/j.bbrc.2006.02.022"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Ma X, Zhao JY, Zhao ZL, Ye J, Li SF, Fang HH, Gu MN, Hu YW, Qin ZS: Propofol Attenuates Lipopolysaccharide-Induced Monocyte Chemoattractant Protein-1 Production Through Enhancing apoM and foxa2 Expression in HepG2 Cells. Inflammation, 2015; 38: 1329-1336","DOI":"10.1007\/s10753-014-0104-y"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Zheng L, Feng Y, Shi Y, Zhang J, Mu Q, Qin L, Berggren-Soderlund M, Nilsson-Ehle P, Zhang X, Luo G, Xu N: Intralipid decreases apolipoprotein M levels and insulin sensitivity in rats. PLoS One, 2014; 9: e105681","DOI":"10.1371\/journal.pone.0105681"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Luo G, Feng Y, Zhang J, Mu Q, Shi Y, Qin L, Zheng L, Berggren-Soderlund M, Nilsson-Ehle P, Zhang X, Xu N: Rosiglitazone enhances apolipoprotein M (Apom) expression in rat's liver. Int J Med Sci, 2014; 11: 1015-1021","DOI":"10.7150\/ijms.8330"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Kumaraswamy SB, Linder A, Akesson P, Dahlback B: Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes. Crit Care, 2012; 16: R60","DOI":"10.1186\/cc11305"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Michels M, Japtok L, Alisjahbana B, Wisaksana R, Sumardi U, Puspita M, Kleuser B, de Mast Q, van der Ven AJ: Decreased plasma levels of the endothelial protective sphingosine-1-phosphate are associated with dengue-induced plasma leakage. J Infect, 2015; 71: 480-487","DOI":"10.1016\/j.jinf.2015.06.014"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Palmiere C, Bonsignore A, Augsburger M: Measurement of apolipoprotein M in sepsis-related deaths. Clin Chem Lab Med, 2015; 53: e93-96","DOI":"10.1515\/cclm-2014-0709"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Christoffersen C, Nielsen LB: Apolipoprotein M--a new biomarker in sepsis. Crit Care, 2012; 16: 126","DOI":"10.1186\/cc11320"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Tong X, Peng H, Liu D, Ji L, Niu C, Ren J, Pan B, Hu J, Zheng L, Huang Y: High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate. Cardiovasc Diabetol, 2013; 12: 27","DOI":"10.1186\/1475-2840-12-27"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Frej C, Mendez AJ, Ruiz M, Castillo M, Hughes TA, Dahlback B, Goldberg RB: A Shift in ApoM\/S1P Between HDL-Particles in Women With Type 1 Diabetes Mellitus Is Associated With Impaired Anti-Inflammatory Effects of the ApoM\/S1P Complex. Arterioscler Thromb Vasc Biol, 2017; 37: 1194-1205","DOI":"10.1161\/ATVBAHA.117.309275"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Niu N, Zhu X, Liu Y, Du T, Wang X, Chen D, Sun B, Gu HF: Single nucleotide polymorphisms in the proxi mal promoter region of apolipoprotein M gene (apoM) confer the susceptibility to development of type 2 diabetes in Han Chinese. Diabetes Metab Res Rev, 2007; 23: 21-25","DOI":"10.1002\/dmrr.641"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Zhou JW, Tsui SK, Ng MC, Geng H, Li SK, So WY, Ma RC, Wang Y, Tao Q, Chen ZY, Chan JC, Ho YY: Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. PLoS One, 2011; 6: e17324","DOI":"10.1371\/journal.pone.0017324"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Galvani S, Sanson M, Blaho VA, Swendeman SL, Conger H, Dahlback B, Kono M, Proia RL, Smith JD, Hla T: HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal, 2015; 8: ra79","DOI":"10.1126\/scisignal.aaa2581"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Kurano M, Hara M, Tsuneyama K, Sakoda H, Shimizu T, Tsukamoto K, Ikeda H, Yatomi Y: Induction of insulin secretion by apolipoprotein M, a carrier for sphingosine 1-phosphate. Biochim Biophys Acta, 2014; 1841: 1217-1226","DOI":"10.1016\/j.bbalip.2014.05.002"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Blaho VA, Galvani S, Engelbrecht E, Liu C, Swendeman SL, Kono M, Proia RL, Steinman L, Han MH, Hla T: HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature, 2015; 523: 342-346","DOI":"10.1038\/nature14462"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Rivera J, Proia RL, Olivera A: The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol, 2008; 8: 753-763","DOI":"10.1038\/nri2400"},{"key":"95","unstructured":"95) Knapp M, Baranowski M, Czarnowski D, Lisowska A, Zabielski P, Gorski J, Musial W: Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit, 2009; 15: CR490-493"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler MH, Brocker-Preuss M, Budde T, Erbel R, Heusch G, Levkau B: Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol, 2010; 105: 821-832","DOI":"10.1007\/s00395-010-0112-5"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Knapp M, Lisowska A, Zabielski P, Musial W, Baranowski M: Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction. Prostaglandins Other Lipid Mediat, 2013; 106: 53-61","DOI":"10.1016\/j.prostaglandins.2013.10.001"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Sattler K, Lehmann I, Graler M, Brocker-Preuss M, Erbel R, Heusch G, Levkau B: HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis. Cell Physiol Biochem, 2014; 34: 172-184","DOI":"10.1159\/000362993"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Jiao GQ, Yuan ZX, Xue YS, Yang CJ, Lu CB, Lu ZQ, Xiao MD: A prospective evaluation of apolipoprotein M gene T-778C polymorphism in relation to coronary artery disease in Han Chinese. Clin Biochem, 2007; 40: 1108-1112","DOI":"10.1016\/j.clinbiochem.2007.04.023"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Xu WW, Zhang Y, Tang YB, Xu YL, Zhu HZ, Ferro A, Ji Y, Chen Q, Fan LM: A genetic variant of apolipoprotein M increases susceptibility to coronary artery disease in a Chinese population. Clin Exp Pharmacol Physiol, 2008; 35: 546-551","DOI":"10.1111\/j.1440-1681.2007.04822.x"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/1\/25_RV17010\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T19:58:11Z","timestamp":1602532691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/1\/25_RV17010\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv17010","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}